NuProbe Global and CarrierGene Biotech Co. Ltd. (Suzhou, China) announced the successful completion of their recent merger and integration. The new company will operate under the English brand NuProbe Global and the Chinese brand阅尔 (Yue Er).
NuProbe Global launches VarTrace™ product line of Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies (VAF) down to 0.1%.
George M. Church, Ph.D., Professor of Genetics at Harvard Medical School, and David R. Walt, Ph.D., Professor of Pathology at Harvard Medical School will form NuProbe’s Scientific Advisory Board.
NuProbe raised $11 million to continue development of ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases. The Series A funding was co-led by Sequoia China and Serica Partners.